•  
  •  

News Releases

SenesTech Reports Sale of ContraPest For Use at A National Park Service Site in Washington D.C.

WASHINGTON and FLAGSTAFF, Ariz., Nov. 27, 2017 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES) received an initial order for ContraPest from Guest Services, Inc. (GSI), the National Park Service concessionaire adjacent to the Thomas Jefferson Memorial in Washington, D.C. The initial order is part of a pilot rat control program developed with the National Park Service (NPS), which manages 24 sites in the District of Columbia, and GSI, the NPS concessionaire at that location. This program will be using ContraPest, SenesTech's lead product for controlling rodent infestations through fertility control.

SenesTech, Inc. is a leader in technology for managing animal pest populations through fertility control.

"We are excited to launch this project to demonstrate one of the intended uses of ContraPest, a sustainable solution to an as yet unconquered rodent problem in a public area where sustained use of poison is not optimal," said Dr. Loretta P. Mayer, SenesTech's co-founder and CEO. "With the multiple National Park Service sites in the District of Columbia, this concept launch can provide a coordinated response to this growing problem. This is an ideal situation for which ContraPest was designed; the anchor tool in an integrated pest management approach which is embraced by the pest control industry at large."

About SenesTech 

SenesTech has developed an innovative technology for managing animal pest populations through fertility control as opposed to a lethal approach.

ContraPest's novel technology and approach targets the reproductive capabilities of both sexes in rat populations, inducing egg loss in female rats and impairing sperm development in males. Using a proprietary bait delivery method, ContraPest is dispensed in a highly palatable liquid formulation that promotes sustained consumption by rat communities. ContraPest is designed, formulated and dispensed to be low hazard for handlers and non-target species such as wildlife, livestock and pets, where the active ingredients break down rapidly, unlike rodenticides. In contrast, the historical approach to managing rat pest populations, rodenticides, carries a high risk of environmental contamination and the poisoning of non-target animals, pets and children. ContraPest is a Restricted Use product.

We believe our innovative non-lethal approach, targeting reproduction, is more humane, less harmful to the environment, and more effective in providing a sustainable solution to pest infestations than traditional lethal pest management methods.  We believe ContraPest® will establish a new paradigm in rodent control, resulting in improved performance in rodent control over rodenticides, without the negative environmental effects of rodenticidesFor more information visit the SenesTech website at www.senestech.com.

Safe Harbor Statement

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors and other risks identified in our filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACT:  

Investor: Robert Blum, Joe Dorame, Joe Diaz, Lytham Partners, LLC, 602-889-9700, senestech@lythampartners.com

Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., 928-779-4143

 

SOURCE SenesTech, Inc.


print email pdf